Neurizon

November marked #NationalFamilyCaregiversMonth - a dedicated moment to recognise the incredible individuals whose compassion and commitment support those who need it most. As the month comes to a close, we’re reminded of the quiet strength and resilience caregivers show every single day, powerfully captured in the “hidden costs” highlighted by the Live Like Lou Foundation.

Repurposed Sheep Antiparasitic Monepantel (NUZ-001) Enters HEALEY-ALS Platform Trial | https://lnkd.in/gmnMy9v2 Monepantel (NUZ-001) is a veterinary anthelmintic being repurposed for ALS that is now advancing in an ALS Platform Trial. An mTOR inhibitor that induces autophagy, Neurizon's NUZ-001, aims to enhance the clearance of aggregation-prone proteins, a hallmark of ALS. Originally, the approved veterinary liquid formulation, Zolvix®, was assessed in humans but was unpalatable with a high frequency of gastrointestinal adverse events, leading to its reformulation into an oral tablet. The Ph. 1 trial met primary safety endpoints, with observations of mTOR PD biomarker changes and CSF exposure. The compound is the eighth therapy to enroll in the HEALEY-ALS platform trial, an operation that allows for multiple and continuous evaluation of therapies for the same disease, cutting time and cost of development to assess clinical candidates. NUZ-001 will begin dosing in the HEALEY Ph. 2/3 trial Q4 of 2025. Read it on Drug Hunter: https://lnkd.in/gmnMy9v2

This weekend, Team Neurizon, led by our team captain Stacie Seidel joins the Walk to Defeat ALS in Boston — a wonderful initiative led by the The ALS Association to gather ALS community and fund care, advocacy, and groundbreaking research. 💙 Neurizon will match every donation made to Team Neurizon — doubling your impact for ALS. It's not too late to join us or donate to help accelerate hope, research, and care for people living with ALS. You can do so by visiting our Team Neurizon page at the event website: https://lnkd.in/eicHPFkv Stacie Seidel, Jeffrey Brown, Michael Thurn, Althea Wong-Achorn #WalktoDefeatALS #ALS #NeurizonTherapeutics #NUZ001 #HorizonOfHope #EveryStepCounts #DoubleYourImpact

Walking to Defeat ALS this weekend in Boston with The ALS Association! This cause is deeply personal for me. My father has been courageously battling ALS for the past five years, and every step I take is for him and for every family facing this disease. I’m grateful to be the Team Captain for Neurizon, and to walk alongside an amazing group of colleagues who are as passionate about finding a cure as I am. If you’re in Boston, please come out and meet the Neurizon team this Sunday. And if you’d like to support the cause, Neurizon is matching all donation and every bit helps in the fight against ALS. You can contribute here: https://lnkd.in/eicHPFkv  #MoreThanADiagnosis #ALS #MND #NeurizonTherapeutics Althea Wong-Achorn

The Australian Patent Office has granted a new patent covering NUZ-001 for the treatment of neurodegenerative diseases — including ALS/MND, Alzheimer’s, Huntington’s, and Parkinson’s disease. This complements our U.S. patent granted earlier this year, extending protection across key global markets through to May 2041. Together, these patents strengthen Neurizon’s commercial pathway for NUZ-001 and mark another step forward in delivering next-generation treatments that make a real difference in the lives of people living with neurodegenerative diseases. For the full announcement, please visit our investor hub at: https://lnkd.in/eAXkB3US #NeurizonTherapeutics #NUZ001 #ALS #MND #NeurodegenerativeDiseases #Innovation #HorizonOfHope

💙 Double your impact for ALS! Every dollar you donate, Neurizon will match — step for step. On October 26, Team Neurizon is proud to walk alongside the ALS community at the Walk to Defeat ALS in Boston. To honour those living with ALS and the families who walk beside them, we’re matching every donation made to Team Neurizon — doubling your impact and helping the The ALS Association continue its critical work funding care, research, and advocacy. Every contribution fuels progress — every step brings us closer to making a difference for those living with ALS. 💙 Donate or join Team Neurizon: https://lnkd.in/eicHPFkv Althea Wong-Achorn Stacie Seidel

💙 Double your impact for ALS! Every dollar you donate, Neurizon will match — step for step. On October 26, Team Neurizon is proud to walk alongside the ALS community at the Walk to Defeat ALS in Boston. To honour those living with ALS and the families who walk beside them, we’re matching every donation made to Team Neurizon — doubling your impact and helping the The ALS Association continue its critical work funding care, research, and advocacy. Every contribution fuels progress — every step brings us closer to making a difference for those living with ALS. 💙 Donate or join Team Neurizon: https://lnkd.in/eicHPFkv Althea Wong-Achorn Stacie Seidel

We’re proud to participate in the 2025 NEALS Annual Meeting in Clearwater, Florida — one of the world’s leading gatherings dedicated to advancing research and care in Amyotrophic Lateral Sclerosis (ALS). This year, Team Neurizon will contribute two scientific posters that highlight both our preclinical research and collaborative innovation: 🧠 Preclinical Characterization of NUZ-001: A Brain-Penetrant Small Molecule That Reduces TDP-43 Aggregation in ALS Models — presented by Dr Jeffrey Brown, Chief Scientific Advisor, showcasing preclinical findings supporting NUZ-001’s potential to address shared disease mechanisms in ALS and other neurodegenerative conditions. 📊 Leveraging External Controls from PRO-ACT for Exploratory Efficacy Assessment in Early-Phase ALS Trials — a collaboration with Berry Consultants, Brigham Young University, and Duke University, and presented by Melanie Quintana, Ph.D, Director Berry Consultants, demonstrating innovative statistical approaches to improve early-phase ALS trial interpretation and design. The NEALS Meeting provides an invaluable opportunity to connect with global experts, patient advocates, and clinical collaborators — including partners from the HEALEY ALS Platform Trial — as we continue to advance science that aims to make a meaningful difference for people living with ALS/MND. 🔗 Learn more about the event: https://meeting.neals.org Reach out to our team on site for a catch-up: Michael Thurn, Sharon Tamir and Jeffrey Brown #NeurizonTherapeutics #NUZ001 #ALS #MND #NeuroDegenerativeDiseases

We’re pleased to share that the U.S. FDA has lifted the clinical hold on NUZ-001, our lead investigational therapy for Amyotrophic Lateral Sclerosis (ALS) — marking a pivotal regulatory milestone that clears the way for inclusion in the HEALEY ALS Platform Trial, expected to commence in Q4 CY2025. This milestone confirms the strength of our preclinical safety and manufacturing data and reflects our commitment to advancing rigorous, patient-focused science. It represents a significant step forward in enabling the continued clinical evaluation of NUZ-001 for people living with ALS — a disease with urgent and unmet medical need. For more information on this announcement and upcoming milestones, read the full release here: https://lnkd.in/e79SjjuD #NeurizonTherapeutics #NUZ001 #ALS #MND #NeuroDegenerativeDiseases #HorizonOfHope #OpenIND

Every step counts in the fight against ALS. ALS slowly robs people of the ability to walk, speak, swallow, and breathe — with an average life expectancy of only 2–5 years after diagnosis. That’s why Team Neurizon, led by our team captain Stacie Seidel, is joining the Walk to Defeat ALS in Boston on October 26, organised by the The ALS Association. The event raises vital funds to provide care and support for people living with ALS today, while also driving bold research aimed at finding effective treatments and, ultimately, a cure. Every step we take is for the patients, families, and carers living with ALS/MND. Join Team Neurizon and support with a donation: https://lnkd.in/eCJ8f4u3 Together, we can help change the statistics. Althea Wong-Achorn Michael Thurn